A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Inclusion Criteria: * Meets ICSD-3 criteria for IH or Narcolepsy Type 2 and not undergoing pharmacologic treatment for the condition * Usual nightly total sleep at least 6 hours as single major rest period without naps * Epworth Sleepiness Scale of 10 or greater * Males or females age 18 to 65 years Exclusion Criteria: * Any disorder causing hypersomnia other than IH or Narcolepsy Type 2 * Usual bedtime later than midnight * Seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years * Beck Depression Inventory score greater than 19 * Beck Anxiety Inventory score greater than 15 * Significant history of or current suicidal ideation or behavior * BMI less than 18 kg/m2 or greater than 39 kg/m2 * Positive toxicology screen or breathalyzer test * Clinically significant abnormal findings on safety assessments * Any significant medical or psychiatric disease or any condition that would put the patient at risk by participating in the study